Global X Japan Co. Ltd. Raises Holdings in AbbVie Inc. $ABBV

Global X Japan Co. Ltd. raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 587.7% in the third quarter, Holdings Channel.com reports. The fund owned 25,664 shares of the company’s stock after buying an additional 21,932 shares during the quarter. AbbVie comprises approximately 0.5% of Global X Japan Co. Ltd.’s holdings, making the stock its 27th largest position. Global X Japan Co. Ltd.’s holdings in AbbVie were worth $5,942,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ellenbecker Investment Group grew its holdings in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA lifted its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its position in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares in the last quarter. Hobart Private Capital LLC grew its stake in AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after buying an additional 48 shares during the period. Finally, Rise Advisors LLC increased its position in shares of AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock worth $336,000 after acquiring an additional 48 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 0.6%

NYSE:ABBV opened at $230.18 on Thursday. The stock has a market cap of $406.81 billion, a price-to-earnings ratio of 174.38, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The business’s 50-day simple moving average is $226.65 and its 200 day simple moving average is $212.00.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Analyst Ratings Changes

ABBV has been the topic of several recent research reports. Evercore ISI lifted their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Morgan Stanley increased their target price on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.